RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) — Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medication corporate, nowadays introduced that its not unusual inventory will transition from buying and selling on The Nasdaq Capital Marketplace to the OTCQB Project Marketplace on Tuesday, Would possibly 5, 2026. This transition follows the receipt by way of Sangamo of a understand from The Nasdaq Inventory Marketplace LLC indicating that Sangamo’s not unusual inventory might be delisted from the Nasdaq Capital Marketplace because of non-compliance with Nasdaq’s minimal bid value requirement. Sangamo intends to request a listening to from Nasdaq to attraction the delisting resolution. The listening to is not going to keep the suspension of buying and selling of Sangamo’s not unusual inventory, and buying and selling of Sangamo’s not unusual inventory on The Nasdaq Capital Marketplace is predicted to be suspended on the open of buying and selling on Would possibly 5, 2026.
Sangamo has secured acclaim for its not unusual inventory to be quoted at the OTCQB Project Marketplace, operated by way of OTC Markets Staff. Sangamo expects its not unusual inventory to start out buying and selling at the OTCQB Project Marketplace underneath its current buying and selling image, SGMO, on the open of buying and selling on Tuesday, Would possibly 5, 2026. For quotes or additional info, buyers would possibly talk over with www.otcmarkets.com.
The transition of buying and selling onto the OTCQB Project Marketplace isn’t anticipated to lead to subject matter affects to Sangamo’s trade or operations. Sangamo stays thinking about pursuing alternatives to lift further capital, together with an review of all strategic choices to maximise the price of its property, and all over the method has been recommended by way of an international funding financial institution. Sangamo is these days negotiating more than one attainable trade construction transactions and expects to proportion main points on those attainable transactions if and when definitive agreements are finished.
Sangamo will proceed to supply updates on trade development and fiscal ends up in accordance with acceptable Securities and Change Fee laws. Additional info associated with this announcement might be incorporated in a Present Record on Shape 8-Ok to be filed with the SEC.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medication corporate devoted to translating ground-breaking science into drugs that change into the lives of sufferers and households troubled with critical neurological sicknesses who don’t have good enough or any remedy choices. Sangamo believes that its zinc finger epigenetic regulators are preferably suited for probably cope with devastating neurological issues and that its capsid discovery platform can amplify supply past these days to be had intrathecal supply capsids, together with within the central anxious gadget. Sangamo’s pipeline additionally comprises more than one partnered techniques and techniques with alternatives for partnership and funding. To be informed extra, talk over with www.sangamo.com and connect to us on LinkedIn.
Ahead-Taking a look Statements
This press liberate incorporates forward-looking statements in line with Sangamo’s present expectancies. Those forward-looking statements come with, with out limitation, statements on the subject of Sangamo’s expectancies in regards to the transition of Sangamo’s not unusual inventory to the OTCQB Project Marketplace and the timing and affect thereof, expectancies referring to a possible listening to to attraction Nasdaq’s delisting resolution, Sangamo’s plans to pursue further alternatives to lift capital and maximize the price of its property and the possibility of execution of definitive agreements in admire of industrial construction transactions. Those statements don’t seem to be promises of long term efficiency and are topic to sure dangers and uncertainties which might be tricky to expect. Elements that might motive precise effects to vary come with, however don’t seem to be restricted to, dangers and uncertainties associated with Sangamo’s loss of capital assets and wish for really extensive further investment to execute its working plan and to proceed to perform as a going worry, together with the chance that Sangamo will not be able to safe a vital partnership or different transaction, particularly for its Fabry illness program, offering for really extensive prematurely investment within the very close to time period vital to fund its operations and perform as a going worry; the chance that Sangamo might be unsuccessful in interesting the delisting resolution; the consequences of macroeconomic components or monetary demanding situations, together with on account of the continuing in another country conflicts, price lists, geopolitical instability, inflation and fluctuations in rates of interest, at the world trade atmosphere; the unsure analysis and construction procedure, together with the result of scientific trials; the regulatory approval procedure for product applicants; and the possibility of technological trends that obviate applied sciences utilized by Sangamo. Exact effects would possibly vary from the ones projected in forward-looking statements because of dangers and uncertainties that exist in Sangamo’s operations and trade. Those dangers and uncertainties are described extra totally in our Securities and Change Fee filings and studies, together with in our Annual Record on Shape 10-Ok for the 12 months ended December 31, 2025. Ahead-looking statements contained on this announcement are made as of this date, and Sangamo undertakes no responsibility to replace such knowledge with the exception of as required underneath acceptable legislation.
Investor Family members and Media Inquiries
